Hardman & Co Investor Forum 26th February 2019

Last week we were delighted to host our 15th Investor Forum at the offices of DAC Beachcroft. We welcomed 4 interesting companies to present to an audience of 60 sophisticated investors. The audience had the opportunity to learn more about investing in clean energy, a dividend paying gold miner, and two distinct health care companies at different commercial stages.

Click to view all articles for the EPIC: AAZ, GHE, STX
Or click to view the full company profile:
Gresham House plc

Shield Therapeutics Viatris deal has the potential to accelerate sales at a much faster rate (LON:STX)

26th January 2023

Hardman and Co’s Dr Martin discusses Shield Therapeutics plc in this exclusive interview with DirectorsTalk.

Shield Therapeutics positioned for profitability with Viatris deal and its additional capital (VIDEO)

19th January 2023

Shield Therapeutics (LON:STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews. Martin summarises a number of announcements made by the company recently, explains Accrufer has performed in the US, a co-promotion deal with Viatris, changes

Shield Therapeutics: Positioned for growth and profitability

13th January 2023

Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician

Shield Therapeutics: Accrufer momentum building

16th September 2022

Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US, in July 2021, the initial challenge

Shield Therapeutics: Further positive momentum (LON:STX)

16th August 2022

Hardman and Co’s Dr Martin Hall discusses Shield Therapeutics in this exclusive interview with DirectorsTalk.

Shield Therapeutics sales team making considerable inroads (VIDEO)

10th August 2022

Shield Therapeutics plc (LON:STX) is the topic of conversation when Hardman & Co Analyst Dr Martin Hall joins DirectorsTalk Interviews. Despite launching a drug into the US market, Shield has performed really badly over the past 12 months, Martin

Shield Therapeutics: Looking to accelerate positive signals in the US

26th July 2022

Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US in July 2021, the initial

Shield Therapeutics: PBMs have bought in to Accrufer

4th March 2022

Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following the US launch of Accrufer® in July 2021, the initial challenge

Shield Therapeutics: Focused on US market penetration

23rd August 2021

Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Accrufer® has just been launched in the US by Shield, where

Shield Therapeutics: Accrufer® launch on schedule

26th May 2021

Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru®/Accrufer® has been approved by the regulators in both Europe and

Gresham House Energy Storage Fund NAV up 74% to £358.9m

28th April 2021

Gresham House Energy Storage Fund plc (LON:GRID), the UK’s largest utility-scale battery energy storage fund, has announced its second set of annual results since the IPO in November 2018. This covers the 12 months ended 31 December 2020

Gresham House strengthens Institutional Business team

26th April 2021

Gresham House plc, the specialist alternative asset manager, has appointed James Lindsay as Head of Institutional Business. James joins from MFS Investment Management where he was Managing Director and Head of Sales, leading its UK institutional sales team

Virgin Money backs Gresham House Solar Distribution in multimillion pound deal

22nd April 2021

Virgin Money has agreed a new financing partnership with Gresham House – the bank’s largest transaction in the renewable sector to date. This relationship will provide Gresham House Solar Distribution LLP (GHSD) with an £18m revolving credit facility, through a flexible

Gresham House Energy Storage Fund completes acquisition of large utility-scale battery storage project

22nd April 2021

Gresham House Energy Storage Fund PLC (LON:GRID), the UK’s largest operational utility-scale battery storage fund, has completed its acquisition of the c.30MW battery project located near Wester Dechmont, Livingston in West Lothian, Scotland. The Project was acquired for a total enterprise value

Gresham House Ventures invests £2.25m into Metrion Biosciences

13th April 2021

Gresham House Ventures – a growth equity investor specialised in software and digitally driven businesses in the healthcare, consumer and services sectors – has invested £2.25m into Metrion Biosciences, a contract research organisation (CRO) catering to the drug

Gresham House AGM to be held Wednesday 12 May 2021

13th April 2021

Gresham House plc (LON:GHE), the specialist alternative asset manager, has announced that it has published its Report and Accounts for the year ended 31 December 2020 and Notice of Annual General Meeting on the ‘Key Documents’ section of its website https://greshamhouse.com/gresham-house-plc Copies

Blending home and office working a priority for 2021

7th April 2021

Fund managers must manage a seamless integration between office and home working in order to avoid damaging silos. They should also adopt agile methodologies used in the technology market in order to speed up their operations and cope

Gresham House picks Head of Institutional Business

31st March 2021

James Lindsay joined alternative money manager Gresham House as head of institutional business, a spokeswoman confirmed. She did not say whether the position is new or a replacement. Mr. Lindsay is responsible for the strategic development and further expansion

No more posts to show

Be sure to check our sister interview main ratings news website